Clinically, TNBC is defined as the subtype tested negative for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), accounting for 15–20% of all breast cancers [1, 2]. Here, ESR1 is linked to breast carcinoma.